Bora Biologics Supports Commercial Launch of RAPClot™ Blood Collection Tubes in Japan
Bora Biologics is pleased to support the commercial launch of Q‑Sera’s RAPClot™ blood collection tubes in Japan, introduced by Terumo Corporation under the VenoJect II RAPClot™ product line.
The launch marks the first commercial introduction of Q‑Sera’s patented RAPClot technology, which utilizes recombinant ecarin — a prothrombin activator protein originally identified from snake venom — to significantly accelerate blood clotting and enable rapid production of high‑quality serum for biochemical analysis. The technology reduces turnaround time from sample collection to serum analysis and produces high-quality serum in as little as five minutes, including from anticoagulated blood.
Bora Biologics supported the program through commercial-scale manufacturing of recombinant RAPClot using standard biopharmaceutical production processes. The successful scale-up and production campaign enabled readiness for market introduction in partnership with Terumo Corporation, which holds exclusive rights to manufacture and market the product in Japan.
The launch represents an important milestone for Q‑Sera as it begins broader global commercialization efforts, and highlights Bora Biologics’ capabilities in recombinant protein scale-up, technology transfer, and commercial GMP manufacturing.
We are proud to contribute to innovative technologies that enhance laboratory efficiency and support improved diagnostic workflows.
For full details, view Q‑Sera’s announcement on GlobeNewswire.
